Under-reporting of Adverse Events in the Biomedical Literature

被引:0
|
作者
Ronald N.Kostoff
机构
[1] SchoolofPublicPolicy,GeorgiaInstituteofTechnology
关键词
D O I
暂无
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Purpose: To address the under-reporting of research results, with emphasis on the underreporting/distorted reporting of adverse events in the biomedical research literature.Design/methodology/approach: A four-step approach is used:(1) To identify the characteristics of literature that make it adequate to support policy;(2) to show how each of these characteristics becomes degraded to make inadequate literature;(3) to identify incentives to prevent inadequate literature; and(4) to show policy implications of inadequate literature.Findings: This review has provided reasons for, and examples of, adverse health effects of myriad substances(1) being under-reported in the premiere biomedical literature, or(2) entering this literature in distorted form. Since there is no way to gauge the extent of this under/distorted-reporting, the quality and credibility of the ‘premiere' biomedical literature is unknown. Therefore, any types of meta-analyses or scientometric analyses of this literaturewill have unknown quality and credibility. The most sophisticated scientometric analysis cannot compensate for a highly flawed database.Research limitations: The main limitation is in identifying examples of under-reporting. There are many incentives for under-reporting and few dis-incentives.Practical implications: Almost all research publications, addressing causes of disease, treatments for disease, diagnoses for disease, scientometrics of disease and health issues, and other aspects of healthcare, build upon previous healthcare-related research published. Many researchers will not have laboratories or other capabilities to replicate or validate the published research, and depend almost completely on the integrity of this literature. If the literature is distorted, then future research can be misguided, and health policy recommendations can be ineffective or worse.Originality/value: This review has examined a much wider range of technical and nontechnical causes for under-reporting of adverse events in the biomedical literature than previous studies.
引用
收藏
页码:10 / 32
页数:23
相关论文
共 50 条
  • [1] Under-reporting of Adverse Events in the Biomedical Literature
    Ronald N.Kostoff
    Journal of Data and Information Science, 2016, (04) : 10 - 32
  • [2] Under-reporting of maternal and perinatal adverse events in New Zealand
    Farquhar, Cynthia
    Armstrong, Sarah
    Kim, Boa
    Masson, Vicki
    Sadler, Lynn
    BMJ OPEN, 2015, 5 (07):
  • [3] Under-reporting of adverse effects of tesofensine
    Astrup, Arne
    Madsbad, Sten
    Breum, Leif
    Jensen, Thomas J.
    Kroustrup, Jens P.
    Larsen, Thomas M.
    LANCET, 2013, 382 (9887): : 127 - 127
  • [4] UNDER-REPORTING OF ADVERSE DRUG-REACTIONS
    BATEMAN, DN
    BRITISH MEDICAL JOURNAL, 1985, 290 (6483): : 1749 - 1749
  • [5] Reporting of adverse drug reactions: predictors of under-reporting in Malaysia
    Aziz, Zoriah
    Siang, Tan Ching
    Badarudin, Nurul Suhaida
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (02) : 223 - 228
  • [6] UNDER-REPORTING OF ADVERSE DRUG-REACTIONS
    INMAN, WHW
    BRITISH MEDICAL JOURNAL, 1985, 290 (6478): : 1355 - 1355
  • [7] Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events
    Noh, Yunha
    Ko, Hwa Yeon
    Kim, Ju Hwan
    Yoon, Dongwon
    Choe, Young June
    Choe, Seung-Ah
    Jung, Jaehun
    Shin, Ju-Young
    EPIDEMIOLOGY AND HEALTH, 2023, 45 : 1 - 7
  • [8] Under-reporting of adverse drug reactions in general practice
    Moride, Y
    Haramburu, F
    Requejo, AA
    Begaud, B
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (02) : 177 - 181
  • [9] Under-Reporting of Adverse Drug ReactionsA Systematic Review
    Lorna Hazell
    Saad A.W. Shakir
    Drug Safety, 2006, 29 : 385 - 396
  • [10] Under-reporting of adverse drug reactions - A systematic review
    Hazell, Lorna
    Shakir, Saad A. W.
    DRUG SAFETY, 2006, 29 (05) : 385 - 396